Thienolate Inhibitors Restore Beta-Lactam Antibiotic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics, particularly β-lactams, face significant resistance due to metallo-beta-lactamases (MBLs), which hydrolyze almost all β-lactam antibiotics, including last resort drugs, and there is a lack of clinically useful inhibitors for Class B MBLs, necessitating the development of broad-spectrum MBL inhibitors for effective combination therapies.
Innovation Solution
A thienolate compound of formula (I) or its pharmaceutically acceptable salt, which acts as a broad-spectrum metallo-beta-lactamase inhibitor, is developed for use in methods of inhibiting MBLs, potentially in combination with β-lactam antibiotic agents to enhance their efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-lactam antibiotics are used to treat bacterial infections, then they effectively inhibit transpeptidases and kill susceptible bacteria, but their activity is compromised by β-lactamases which catalyse hydrolysis of the antibiotic
Solution Approach 1:
The patent introduces thienolate compounds as intermediary substances that bind to β-lactamases (specifically Class B metallo-β-lactamases), preventing these enzymes from hydrolyzing β-lactam antibiotics. The thienolate acts as a mediator between the antibiotic and the enzyme, blocking the harmful interaction while allowing the antibiotic to maintain its therapeutic activity against bacteria.
Solution Approach 2:
The invention converts the harmful β-lactamase enzyme into a beneficial target by designing thienolate compounds that specifically inhibit Class B MBLs. By targeting the enzyme responsible for antibiotic resistance, the treatment transforms the resistance mechanism into a selectable target, allowing combination therapies to overcome resistant strains while preserving β-lactam antibiotic efficacy.
2Adaptability or versatility
If inhibitors of Class A and Class C β-lactamases are used, then the spectrum of activity of partner penicillins and cephalosporins is extended, but there are no clinically useful inhibitors of Class B metallo-BLs
Solution Approach 1:
The thienolate compounds described in the patent exhibit broad-spectrum inhibition activity against multiple classes of β-lactamases, including Class A, Class C, and crucially Class B metallo-β-lactamases. This multi-functional capability fills the therapeutic gap by providing a single inhibitor class that can address diverse β-lactamase-mediated resistance mechanisms, enabling broader antibiotic spectrum extension.
Solution Approach 2:
The patent employs systematic modification of chemical parameters in the thienolate compound structure (substituents on rings A1 and A2, variations in R groups, and n values) to optimize inhibition profiles across different β-lactamase classes. By adjusting these molecular parameters, the compounds achieve effective binding and inhibition of Class B MBLs while maintaining or enhancing activity against other β-lactamase types.
3Reliability
If last resort antibiotics such as carbapenems are used, then they can treat resistant infections, but MBLs inactivate almost all BLs including these last resort antibiotics
Solution Approach 1:
The patent implements a combination therapy approach where thienolate inhibitors are administered alongside β-lactam antibiotics including carbapenems. The thienolate compound performs preliminary action by pre-binding to and inhibiting MBLs before the carbapenem can be degraded, thereby protecting the last-resort antibiotic from inactivation and restoring its efficacy against MBL-producing bacteria.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The thienolate compound effectively inhibits MBLs, thereby potentiating the activity of β-lactam antibiotics, providing a useful approach for the prevention and treatment of bacterial infections caused by resistant strains.
Implementation Method 1
The compounds are therefore useful in potentiating the effects of β lactam antibiotic agents and can be used in combination with β lactam antibiotic agents in the prevention and treatment of bacterial infection... which catalyse β-lactam hydrolysis
Implementation Method 2
MBLs are zinc dependent hydrolases that catalyse β-lactam hydrolysis
Data Source
AI summary
A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1, R3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided.